

PUBLIC SUMMARY DOCUMENT

Product: Omnigon Eakin Dot
Applicant: Omnigon Pty Ltd
Date of SPAP Meeting: 11 April 2016

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Omnigon, sought listing of the Eakin Dot two-piece flat baseplate with mechanical coupling, in subgroup 4(a) of the Stoma Appliance Scheme (SAS) Schedule. The product, including 10 variants, was proposed at the unit price of \$4.141 with a maximum monthly quantity of 30 units.

2. Comparator

The applicant nominated Omnigon Welland Flair 2 (SAS code 9994B) from its own range, which is currently listed in subgroup 4(a), as the comparator. This product is currently listed at the unit price of \$4.141 with a maximum monthly quantity of 30 units.

3. Background

This was the Stoma Product Assessment Panel (SPAP)'s first consideration of this product.

4. Clinical Place for the Product

The proposed product is an alternative for users requiring a two-piece flat baseplate with mechanical coupling. The product is a direct substitute for the comparator currently available in subgroup 4(a).

5. SPAP Comment

Clinical Analysis

The Panel noted that the proposed product provides a floating flange enabling connection of the pouch to baseplate with minimal pressure, and a purple coloured mechanical ring. The baseplate is a foam backed hydrocolloid six sided flower shaped baseplate which the applicant claims will allow greater ability to mould.

The panel agreed that this product is no worse than the nominated comparator.

Economic Analysis

Not undertaken.

Financial Analysis

Listing of this product would be on a cost-minimisation basis compared with the nominated comparator product in subgroup 4(a) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

6. SPAP Recommendation

The SPAP recommended that the Eakin Dot two-piece baseplate, including ten variants, be listed in subgroup 4(a) of the SAS Schedule at the benchmark unit price \$4.141, with a maximum monthly quantity of 10 units.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the

SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Omnigon agrees with SPAP's recommendation.